Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CLDN18.2 Positive”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07460375
What this trial is testing

Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
LigaChem Biosciences, Inc. 191
Early research (Phase 1)Study completedNCT05199519
What this trial is testing

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

Who this might be right for
CLDN18.2 Positive Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd. 7
Not applicableLooking for participantsNCT07427992
What this trial is testing

Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
European Institute of Oncology 70
Early research (Phase 1)Active Not RecruitingNCT06396091
What this trial is testing

Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 12
Early research (Phase 1)Looking for participantsNCT05857332
What this trial is testing

SG1906 for CLDN18.2-Positive Solid Tumors

Who this might be right for
Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT05190575
What this trial is testing

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract Neoplasms
Shanghai Zhongshan Hospital 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07415525
What this trial is testing

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic CancerBorderline Resectable Pancreatic Adenocarcinoma
Zhejiang University 40
Early research (Phase 1)UnknownNCT05472857
What this trial is testing

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Who this might be right for
Gastric CancerPancreatic CancerAdvanced Ovarian Carcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd 30
Testing effectiveness (Phase 2)Study completedNCT01630083
What this trial is testing

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Who this might be right for
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusCLDN18.2-positive Gastric Adenocarcinoma
Astellas Pharma Global Development, Inc. 252
Early research (Phase 1)Looking for participantsNCT06084286
What this trial is testing

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Sichuan University 29
Not applicableUnknownNCT05952375
What this trial is testing

Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial

Who this might be right for
Gastric Cancer
The Affiliated Hospital of Qingdao University 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT05862324
What this trial is testing

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Who this might be right for
Metastatic Solid Tumor
Triumvira Immunologics, Inc. 113
Testing effectiveness (Phase 2)Looking for participantsNCT06587425
What this trial is testing

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07444541
What this trial is testing

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Anova Innovation Limited 84
Testing effectiveness (Phase 2)Looking for participantsNCT06962137
What this trial is testing

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma MetastaticGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Universitaire Ziekenhuizen KU Leuven 100
Testing effectiveness (Phase 2)Looking for participantsNCT06038396
What this trial is testing

RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumor
RemeGen Co., Ltd. 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07483567
What this trial is testing

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
CLDN18.2 PositivePrimary Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 90
Early research (Phase 1)Looking for participantsNCT06350006
What this trial is testing

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Who this might be right for
CLDN18.2-positive Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd. 924
Large-scale testing (Phase 3)Looking for participantsNCT07284134
What this trial is testing

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd. 560
Large-scale testing (Phase 3)Looking for participantsNCT07103668
What this trial is testing

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Who this might be right for
Gastric Adenocarcinoma
Suzhou Immunofoco Biotechnology Co., Ltd 150
Load More Results